A STUDY TO SEE IF HOMOEOPATHIC MEDICINES CAN BE USED TO TREAT CHRONIC KIDNEY DISEASE BY MONITORING SERUM ANION GAP

Phase 2

Completed

• Conditions: Health Condition 1: N183- Chronic kidney disease, stage 3 (moderate)

• Registration Number: CTRI/2022/11/047505
• Lead Sponsor: DR BIJITA MANDAL BG

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2023-08-17
• Last Update Posted: 13 November 2023

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 34

Inclusion Criteria

1.Subjects belonging to the age group 30 to 70.

2. Patients belonging to both sexes.

3. Patients with mild (below 90 mL/min per 1.73m2) to moderate renal dysfunction

or patients who fulfil the diagnostic criteria of chronic kidney disease, GFR <60 mL/min per 1·73m² or Albuminuria (albumin: creatinine ratio [ACR] =30mg/g).

4. Patients with disease conditions that poses a risk to Renal function (long standing Diabetics, Hypertensives)

5. Patients who have been consuming nephrotoxic drugs

Exclusion Criteria

1. End stage renal disease ( < 15 mL/min/1.73 m2) or dialysis at time of enrolment

2. History of solid organ or bone marrow transplantation

3. Active malignancy within 24 months prior to screening or metastatic cancer

4. Severe cognitive impairment (Mini Mental State Examination < 10)

5. Any medical or other reason (e.g., known or suspected inability of the patient to comply with the protocol procedure) in the judgement of the investigators, that the patient is unsuitable for the study

6. Patients who need emergency management.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The difference in the anion gap in patients with mild to <br/ ><br>moderate chronic kidneyTimepoint: 3 months

Secondary Outcome Measures

Name	Time	Method
The difference in the anion gap in patients with mild to <br/ ><br>moderate chronic kidneyTimepoint: 6 months